Singulex heads for $86.25M flotation

Singulex, a diagnostics company based in Alameda, CA, has filed for an $86.25 million IPO. According to the San Francisco Business Times, the company promises a test that can measure previously undetectable levels of cytokines, blood biomarkers that could indicate an increased risk of heart attack. The company is designing and developing a second-generation digital immunoassay monitoring platform, which could come into use in its own laboratories in 2014, and be commercially available by 2016. Nasdaq overview | Article

Suggested Articles

Longitude Capital invests in what its founders call “transformative healthcare companies," working in areas they hope will increase quality of life.

The FDA launched a center of excellence to oversee digital health products such as smartphone apps, wearable devices and software-based treatments.

The immunoassay will measure neurofilament light chain protein levels, found in the blood and cerebrospinal fluid, and linked to nerve damage.